Literature DB >> 1878895

Lymphocyte activation in patients with acute myeloid leukaemia. Evidence for the presence of myeloblast antigen?

S H Lim1, C P Worman, A H Goldstone.   

Abstract

A group of 27 patients with acute myeloid leukaemia (AML), 15 with active disease and 12 in complete remission, were investigated for evidence of T cell activation. The parameters of T cell activation measured were the serum levels of soluble interleukin-2 receptor (sIL-2R), soluble CD4 (sCD4) and soluble CD8 (sCD8) molecules and the proportions of T cells expressing the cytotoxicity-linked cytoplasmic serine esterase. All patients studied with active disease had elevated sIL-2R and sCD8 molecules and an elevated proportion of T cells expressing serine esterase. Patients studied in complete remission also had elevated sIL-2R. sCD8 and serine-esterase-positive T cells, but values were lower than those studied in active disease. These patients were all studied in the absence of any ongoing or recent infection or exposure to homologous blood products, either of which could potentially affect these parameters. In the absence of any obvious alternative cause, we suggest these data indicate that AML leukaemia blast cells may be immunogenic and lead to the activation of cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878895     DOI: 10.1007/bf01741604

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms.

Authors:  G Pizzolo; H Stein; O Josimovic-Alasevic; F Vinante; R Zanotti; M Chilosi; A C Feller; T Diamantstein
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

2.  Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.

Authors:  S H Lim; C Worman; A Jewell; C Tsakona; F J Giles; A Goldstone
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia.

Authors:  A D Ho; M Grossman; L Trümper; A Pezzutto; H Pralle; S Boedewadt-Radzun; U Papendick; B Göd; T Zwingers; W Hunstein
Journal:  Blood       Date:  1990-03-01       Impact factor: 22.113

4.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

Review 5.  Suppressor cell function in solid tumor cancer patients.

Authors:  J Von Roenn; J E Harris; D P Braun
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

Review 6.  Suppressor cells of immune reactivity in malignancy.

Authors:  H Kirchner
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

Review 7.  The soluble interleukin-2 receptor in haematological disorders.

Authors:  G Pizzolo; M Chilosi; G Semenzato
Journal:  Br J Haematol       Date:  1987-12       Impact factor: 6.998

8.  Certain myeloid cells possess receptors for interleukin-2.

Authors:  R J Armitage; A P Lai; P J Roberts; J C Cawley
Journal:  Br J Haematol       Date:  1986-12       Impact factor: 6.998

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Authors:  J Fujimoto; S Levy; R Levy
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.